New Report Highlights Cancer Workforce Shortage

Action: A new Lancet Oncology Commission report warns that cancer workforce shortages are already limiting diagnosis, treatment, and survival.¹ The Commission projects that this global shortage could reach roughly 100 million personnel by 2050, with the largest gaps in nursing and diagnostic specialties.

Trusted Insights for What’s Ahead^®

• Shortages are not simply a headcount problem; instead, they reflect constraints across the full system. For cancer care, these constraints are especially consequential because effective treatment depends on coordinated capacity across the care continuum.
• The Commission estimates that one in three cancers already go undiagnosed globally and identifies particularly large projected shortages in nursing and diagnostic specialties such as radiology and pathology.
• The report also emphasizes that technology should augment, not replace, clinicians.
• The Commission frames investment into the cancer workforce in economic terms, projecting that workforce scale-up could avert 170 million cancer deaths between 2030 and 2050 and produce significant net economic benefits.
• In the US, national cancer-attributable medical care costs are projected to exceed $245 billion by 2030, even before accounting for broader productivity losses.² Globally, the economic burden of cancer is projected to reach about $25.2 trillion from 2020 to 2050.³ While global in scope, the report findings are directly relevant to US health policy and intersect with current Federal cancer care priorities. CMS is continuing the Enhancing Oncology Model, a voluntary payment model focused on coordinated, high-quality, patient-centered cancer care for Medicare beneficiaries receiving systemic chemotherapy.⁴ The Administration has also emphasized Medicare drug price negotiations involving cancer and chronic disease treatments as part of its broader cost-containment agenda.⁵

• What this means for business
  • Cancer workforce shortages affect employers through delayed diagnosis, higher treatment costs, reduced productivity, and greater pressure on workers and families navigating serious illness. The Commission’s recommendations on workforce registries, cancer registries, and stronger workforce planning would help identify gaps in access, diagnostics, and treatment capacity.
  • Employers have a strong interest in cancer care capacity because delays in prevention, diagnosis, navigation, and treatment can raise costs, prolong time away from work, and reduce labor force participation.
  • Business can help advance practical solutions through employer-educator partnerships, career pathways, responsible technology adoption, and benefit designs that promote access to high-value cancer care. The Commission emphasizes cross-sector partnerships, digital health, AI, task-shifting, sustainable financing, and workforce training as tools to expand capacity while preserving quality, equity, and accountability.